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ABSTRACT
Reprogramming cell fates towards pluripotent stem
cells and other cell types has revolutionized our under-
standing of cellular plasticity. During the last decade,
transcription factors and microRNAs have become
powerful reprogramming factors for modulating cell
fates. Recently, many efforts are focused on repro-
gramming cell fates by non-viral and non-integrating
chemical approaches. Small molecules not only are
useful in generating desired cell types in vitro for vari-
ous applications, such as disease modeling and cell-
based transplantation, but also hold great promise to be
further developed as drugs to stimulate patients’
endogenous cells to repair and regenerate in vivo. Here
we will focus on chemical approaches for generating
induced pluripotent stem cells, neurons, cardiomy-
ocytes, hepatocytes and pancreatic β cells. Signiﬁ-
cantly, the rapid and exciting advances in cellular
reprogramming by small molecules will help us to
achieve the long-term goal of curing devastating dis-
eases, injuries, cancers and aging.
KEYWORDS reprogramming, small molecules, stem
cells, cell fates
INTRODUCTION
Studies of developmental biology have demonstrated that
the zygote is totipotent and can gradually differentiate into
all tissues and organs of the human body, that is composed
by more than 200 types of specialized cells. However, the
demonstration of interchanging cell fates and converting
one cell type into another by different strategies, such as
nuclear transfer or cell fusion, has challenged the traditional
cognition of development and regeneration (Gurdon, 1962;
Tada et al., 1997). In 2006, Yamanaka and Takahashi
reported the development of the induced pluripotent stem
cell (iPSC) technology, which can convert somatic cells to
iPSCs using four transcription factors (TFs) (Takahashi and
Yamanaka, 2006). During the last 10 years, iPSC technol-
ogy has provided many fundamental insights into the
molecular mechanisms of cell fate transition, and already
demonstrated promising results in various applications,
including disease modeling, drug screening, and cell-based
therapy (Takahashi and Yamanaka, 2016). Recently, dif-
ferent combinations of lineage-speciﬁc TFs have been
screened and applied to generate various cell types,
including neurons, cardiomyocytes, hepatocytes, and pan-
creatic β cells (Huang et al., 2011; Ieda et al., 2010; Vier-
buchen et al., 2010; Zhou et al., 2008). However, TF-based
reprogramming approaches face many challenges in efﬁ-
ciency, safety, and in vivo delivery. As a novel and
promising solution, small molecules are easy to apply and
remove, more efﬁcient and amenable to scale up. Small
molecules not only are useful in generating desired cell
types in vitro for various applications, but also can be fur-
ther developed as drugs to stimulate patients’ endogenous
cells to repair and regenerate in vivo.
In this review, we will focus on making iPSCs, neurons,
cardiomyocytes, hepatocytes and pancreatic β cells by small
molecules (Fig. 1). Many interesting small molecules have
been identiﬁed that can signiﬁcantly promote cellular repro-
gramming (Table 1). The rapid and exciting advances in
cellular reprogramming by small molecules will undoubtedly
advance biomedical studies and clinical translation.
PLURIPOTENT REPROGRAMMING
In 2006, the ﬁrst generation of iPSCs were derived by using
four transcription factors (Oct4, Sox2, Klf4, and c-Myc,
termed OSKM) (Takahashi and Yamanaka, 2006). During
the last 10 years, substantial efforts have been made to
improve the efﬁciency and safety of iPSC reprogramming
by non-integrating viral vectors, synthetic RNAs, recombi-
nant proteins and small molecules (Gonzalez et al., 2011).
Particularly, screenings have been applied to identify
chemical compounds that can replace individual or multiple











Yamanaka factors. Ichida et al. carried out a high-content
chemical screening and identiﬁed RepSox (also named as
E616452, an ALK5 inhibitor) as a chemical replacer of
Sox2 (Ichida et al., 2009). The authors suggested that
RepSox promoted the completion of reprogramming
through induction of Nanog. In addition, RepSox possibly
promoted mesenchymal-to-epithelial transition (MET) during
the early phase of reprogramming (Li et al., 2010). Using a
Nanog-Luciferase reporter as readout, Kenpaullone was
found to functionally replace Klf4 in the presence of OSM
(Lyssiotis et al., 2009). Shi et al. found that the combination
of BIX01294 and Bayk8644 or BIX01294 and RG108
enabled OK-induced reprogramming of mouse ﬁbroblasts,
and Li et al. further reported successful OK-reprogramming
of human somatic cells by using CHIR99021 and Tranyl-
cypromine (also named Parnate) (Li et al., 2009; Shi et al.,
2008). Huangfu et al. reported that Valproic acid (VPA)
could promote OS-induced reprogramming of human
ﬁbroblasts (Huangfu et al., 2008). Taken together, these
studies demonstrated that epigenetic regulators play
important roles in iPSC reprogramming. Subsequently,
several groups have focused on Oct4-only reprogramming
by employing different chemical cocktails. Chen et al. found
that bone morphogenetic proteins (BMPs) could support
efﬁcient mouse Oct4-alone reprogramming partly through
the promotion of MET (Chen et al., 2011). Interestingly,
Yuan et al. reported that AMI-5 and A83-01 enabled Oct4-
induced reprogramming of mouse ﬁbroblasts. Remarkably,
these Oct4-only iPSCs were truly pluripotent and could give
rise to live-born pups by tetraploid complementation assay
(Yuan et al., 2011). Furthermore, Li et al. identiﬁed a
speciﬁc chemical combination, including VPA, CHIR99021,
E616452 and Tranylcypromine, which was sufﬁcient to
reprogramming mouse ﬁbroblasts to iPSCs with Oct4 alone
(Li et al., 2011). Subsequently, some interesting chemical
substitutes of Oct4 in mouse iPS-reprogramming were
identiﬁed, including Forskolin, D4476, and 2-Methyl-5-hy-
droxytryptamine (2-Me-5-HT) (Hou et al., 2013).
All chemical induced pluripotent reprogramming can
provide a promising paradigm for cell fate transitions. In
2013, Hou et al. demonstrated successful reprogramming of
mouse cells into iPS cells for the ﬁrst time by using a novel
cocktail of seven small molecules, including VPA,
CHIR99021, E616452, Tranylcypromine, Forskolin,
3-deazaneplanocin A (DZNep), and TTNPB (Hou et al.,
2013). Further reﬁnement of this all-chemical reprogramming
led a 1000-fold greater efﬁciency with additional small
molecules, including AM580, EPZ004777, SGC0946, and
5-aza-2-deoxycitidine (5-aza-dC) (Zhao et al., 2015b).
Interestingly, chemical induced pluripotent reprogramming
process required the early formation of extra-embryonic
endoderm (XEN)-like cells and a late transition from XEN-
like cells to iPSCs, which fundamentally distinct from the
pathway of TF-induced pluripotent reprogramming. How-
ever, it is still largely unknown how small molecules activate









Figure 1. Reprogramming cell fates by small molecules. Chemical approaches can be widely applied to manipulate cell fates and
states, including pluripotent reprogramming, directed differentiation, and lineage reprogramming. Small molecules not only are useful
in generating functional cell types, such as cardiomyocytes, hepatocytes, pancreatic β cells, and neurons, but also can provide a
better understanding of the detailed mechanisms underlying speciﬁc reprogramming processes.
REVIEW Xiaojie Ma et al.









Table 1. Representative small molecules for reprogramming cell fates
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enable cell fate transitions. The remaining question is obvi-
ous: how to achieve chemical induced pluripotent repro-
gramming of human cells? We previously made some
progress and reported that a chemical cocktail of Sodium
butyrate (NaB), Parnate, PS48, CHIR99021, A83-01 and
PD0325901 enabled OCT4-induced reprogramming of
human primary somatic cells (Zhu et al., 2010). These
human OCT4-only iPSCs were pluripotent and could give
rise to cells of all three germ layers both in vitro and in vivo.
Further mechanistic studies demonstrated that a metabolic
switch from oxidative phosphorylation to glycolysis is an
important step in iPSC reprogramming. More efforts are
required to identify chemical substitutes for OCT4 in human
cell reprogramming. The demonstration of human pluripotent
reprogramming by an all-chemical approach will greatly
beneﬁt the study of stem cell biology and regenerative
medicine.
NEURAL REPROGRAMMING
An increasing number of people suffer from neurodegener-
ative disorders, such as Alzheimer’s disease and Parkin-
son’s disease, as life expectancy further extends. It is not
feasible to obtain sufﬁcient amounts of patient speciﬁc neural
cells for disease modeling and drug development. In the last
few years, great progress has been made using TF-based
direct reprogramming towards induced neurons (iNs) or
induced neural stem cells (iNSCs).
In 2010, Vierbuchen et al. ﬁrstly reported that mesodermal
mouse ﬁbroblasts could be rapidly and efﬁciently repro-
grammed into ectodermal iNs by using three TFs: Brn2,
Ascl1, and Myt1 l (BAM) (Vierbuchen et al., 2010). Subse-
quently, BAM plus NEUROD1 was applied for neuronal
reprogramming of human cells (Pang et al., 2011). So far, a
number of groups have generated different subtypes of
neurons by combining BAM with speciﬁc TFs that play an
important role in the development of speciﬁc neuron sub-
types (Caiazzo et al., 2011; Kim, 2011; Pang et al., 2011;
Son et al., 2011). Besides TFs, microRNAs, such as miR-9
and miR-124, can also facilitate neuronal reprogramming
(Ambasudhan et al., 2011; Yang et al., 2016; Yoo et al.,
2011). Obviously, it is desirable to develop non-viral and non-
integrative iN reprogramming approaches by small
molecules. In 2015, two simultaneous articles reported the
successful generation of iN from mouse and human ﬁbrob-
lasts via chemical-only approaches (Hu et al., 2015; Li et al.,
2015). Li et al. showed that mouse ﬁbroblasts could be
converted into neurons by using an optimal cocktail of four
small molecules (Forskolin, ISX9, CHIR99021, and
I-BET151, termed FICB) (Li et al., 2015). The authors sug-
gested that I-BET151, a BET family protein inhibitor, sup-
pressed the ﬁbroblast-speciﬁc program, and ISX9 activated
the expression of endogenous neurogenic transcription
factors, which synergistically promoted neuronal conversion
(Li et al., 2015). Hu et al. demonstrated the generation of
neurons from human ﬁbroblasts using a small molecule
cocktail (VPA, CHIR99021, RepSox, Forskolin, SP600125,
GO6983, Y-27631, and Dorsomorphin) (Hu et al., 2015).
Furthermore, via this chemical cocktail, ﬁbroblasts from
familial Alzheimer’s disease patients could also be repro-
grammed to iNs. Such cells can be used for in vitro disease
modeling and drug screenings (Hu et al., 2015). Subse-
quently, Zhang et al. reported that sequential addition of a
cocktail of small molecules (LDN193189, SB431542,
TTNPB, Thiazovivin (Tzv), CHIR99021, VPA, DAPT,
Smoothened agonist (SAG), and Purmorphamine) can
reprogram human astrocytes into functional neurons (Zhang
et al., 2015). Mechanistically, these small molecules inhibited
glial but activated neuronal signaling pathways through
epigenetic and transcriptional modulation. Remarkably,
these human iNs were functional and could survive more
than 5 months under cell culture conditions.
Compared with neurons, expandable and multipotent
iNSCs are desirable for downstream applications, like dis-
ease modeling and drug screening. In the past few years,
many groups reported the generation of iNSCs using neural
lineage-speciﬁc TFs. These iNSCs are multipotent and can
differentiate into functional neurons, astrocytes, and oligo-
dendrocytes both in vitro and in vivo (Ring et al., 2012;
Zhou and Tripathi, 2012). Recently, we achieved both
mouse and human iNSC reprogramming by a cell-activation
signaling-directed (CASD) strategy (Kim et al., 2011; Zhu
et al., 2015). The CASD strategy uses transient exposure
of somatic cells to reprogramming factors (Oct4, Sox2, Klf4,
and c-Myc) in conjunction with soluble lineage-speciﬁc
signals to reprogram cells into other cell types, such as
Table 1 continued
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iNSCs. Several interesting small molecules could promote
OCT4-mediated iNSC reprogramming process, including
A83-01, CHIR99021, NaB, Lysophosphatidic acid (LPA),
Rolipram and SP600125 (Zhu et al., 2014a). Furthermore,
similar to iN reprogramming, there are also great advances
in iNSC reprogramming by using small molecules alone. In
2014, Cheng and colleagues used three small molecules
VPA, CHIR99021, and RepSox to derive iNPCs from
somatic cells (Cheng et al., 2014). More recently, Zhang
et al. achieved more efﬁcient mouse iNSC reprogramming
by using a cocktail of nine components (CHIR99021,
LDN193189, A83-01, Retinoic acid (RA), Hh-Ag1.5,
RG108, Parnate, SMER28, and bFGF) (Zhang et al.,
2016a). They provided deﬁnitive evidence that these iNSCs
could be reprogrammed from ﬁbroblasts using a genetic
lineage-tracing system. Interestingly, further mechanistic
studies uncovered that these small molecules could grad-
ually and speciﬁcally activate key neurogenic regulators,
such as Sox2, and then facilitated the neural cell fate
transition.
Direct in vivo reprogramming will provide a perspective for
cell-based clinical regenerative therapy (Chen et al., 2015; Li
and Chen, 2016). Glial cells are the most abundant cells in
adult brains and several groups have reported the suc-
cessful TF-based reprogramming of glial cells to neurons or
iNPCs. Niu et al. found that delivery of Sox2 could reprogram
endogenous astrocytes to proliferating neuroblasts and
these neuroblasts further differentiated to functional neurons
that integrated into neural networks in the brain (Niu et al.,
2013). Guo et al. demonstrated that cortical glial cells acti-
vated by injury or disease could be reprogrammed by Neu-
roD1 in vivo (Guo et al., 2014). The further application of
knowledge learned from in vitro chemical screening and
ambitious in vivo chemical screening will undoubtedly
advance this ﬁeld.
CARDIAC REPROGRAMMING
The adult mammalian heart possesses little regenerative
capacity following injury. Cardiac ﬁbroblasts account for a
majority of cells in the heart, and cardiac reprogramming
holds great potentials. In 2010, Ieda et al. reported that
postnatal cardiac ﬁbroblasts could be directly reprogrammed









Figure 2. Potential applications of cellular reprogramming. Cellular reprogramming can provide a large number of functional
cells, which can be used for cell-based transplantation and high-throughput chemical screenings. This technology will help develop
drugs to stimulate patients’ endogenous cells to repair and regenerate in vivo in the near future. Cellular reprogramming by only small
molecules will signiﬁcantly advance biomedical studies and clinical applications, and realize the long-term goal of curing degenerative
diseases, injuries, and aging.
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with a combination of three TFs (Gata4, Mef2c, Tbx5, termed
GMT) (Ieda et al., 2010). Lineage-tracing experiments
showed that the cardiac reprogramming with GMT was a
direct conversion process. Subsequently, other groups
showed that addition of TFs such as Hand2 and Nkx2.5 to
GMT promoted the reprogramming efﬁciency or maturation
of iCMs (Addis and Epstein, 2013; Ifkovits et al., 2014; Song
et al., 2012). Additionally,miRNAs, such as miR-1 and miR-
133, also play important roles in cardiac reprogramming
(Ieda, 2016; Jayawardena et al., 2012; Muraoka et al., 2014;
Nam et al., 2013; Zhao et al., 2015a). Although the efﬁciency
of cardiac reprogramming has been improved in recent
years, the molecular mechanisms of this process are largely
unknown. More recently, Zhou et al. carried out a small-scale
functional screening and identiﬁed that loss of Bmi1 signiﬁ-
cantly promoted mouse cardiac reprogramming. Mechanis-
tically, Bmi1 blocked cardiac reprogramming through direct
interactions with the regulatory regions of many cardiogenic
genes (Zhou et al., 2016). Compared with mouse cardiac
reprogramming, human cardiac reprogramming is much
more challenging to be achieved. Fu et al. showed that GMT
plus ESRRG, MESP1, Myocardin, and ZFPM2 could repro-
gram human ﬁbroblasts to iCMs (Fu et al., 2013). Nam et al.
demonstrated that human ﬁbroblasts could be converted to
iCMs by introduction of GATA4, HAND2, TBX5, Myocardin,
miR-1, and miR-133 under long-term culture (Nam et al.,
2013). Wada et al. found that GMT plus MESP1 and Myo-
cardin could reprogram human ﬁbroblasts to iCMs (Rie et al.,
2013). Such TF-reprogrammed iCMs exhibited sarcomere
formation, calcium transients, and action potentials, but
could not contract spontaneously and robustly. These results
indicated that further improvements are still required for
complete human cardiac reprogramming.
Small molecules can potentially replace TFs and provide
a novel approach for cardiac reprogramming. Interestingly,
the addition of TGF-β inhibitor SB431542 or A83-01
improved the efﬁciency of iCM generation (Fu et al., 2013;
Zhao et al., 2015a). Other small molecules, including
Y-27632, JAK inhibitor I, LY-364947, SD-208 and
GW788388, did also enhance cardiac reprogramming (Lalit
et al., 2016; Zhao et al., 2015a, b). Tamakawa et al. showed
that adding ﬁbroblast growth factor (FGF) 2, FGF10, and
vascular endothelial growth factor (VEGF) to GMTenhanced
cardiac reprogramming about 100-fold compared with GMT
only (Yamakawa et al., 2015). Wang et al. identiﬁed a small
molecule cocktail, including CHIR99021, SB431542, Par-
nate, and Forskolin, that enabled efﬁcient conversion of
mouse ﬁbroblasts into iCMs with Oct4 alone employing the
CASD paradigm. These iCMs spontaneously contracted and
exhibited a ventricular phenotype (Wang et al., 2014).
Recently, there have been signiﬁcant achievements in car-
diac reprogramming by using small molecules alone. Fu
et al. showed that a chemical cocktail (CHIR99021, RepSox,
Forskolin, and VPA) could induce beating clusters of cardiac
cells from mouse ﬁbroblasts. Other small molecules,
including ICARIIN, PD169316 and Rolipram also increased
the efﬁciency of cardiac reprogramming (Fu et al., 2015).
Nan et al. showed that human iCMs could be generated
from ﬁbroblasts by a speciﬁc set of small molecules (Cao
et al., 2016). This combination of nine compounds was ter-
med 9C, including CHIR99021, A83-01, BIX01294, AS8351,
SC1, Y-27632, OAC2, SU16F, and JNJ10198409. Remark-
ably, at both transcriptome and epigenetic levels, these
human iCMs resembled human cardiomyocytes. The
authors observed enrichment of H3K4me3 as well as
H3K27ac, and decrease of H3K27me3 on a cohort of heart
developmental genes during 9C-induced cardiac repro-
gramming. Mechanistically, 9C treatment epigenetically and
transcriptionally activated key cardiac developmental genes
and facilitated the cardiac fate transition. Interestingly, unlike
human iCMs from TF-based reprogramming, these human
9C-induced iCMs uniformly contracted. More efforts are
required to apply this chemical cardiac reprogramming
approach to patient cells.
Expandable and multipotent induced cardiac progenitor
cells (iCPCs) are more suitable for basic studies and trans-
lational applications. Islas et al. found that human dermal
ﬁbroblasts could be converted into cardiac progenitors by
ETS2 and MESP1 overexpression (Islas et al., 2012). After a
screening of multiple cardiac TFs, Lalit et al. reported that a
combination of Mesp1, Tbx5, Gata4, Nkx2.5, and Baf60c
could reprogram mouse ﬁbroblasts into iCPCs (Lalit et al.,
2016). Meanwhile, Zhang et al. demonstrated that ﬁbroblasts
could be induced into expandable iCPCs by the CASD lin-
eage conversion strategy and these iCPCs could be further
long-term expanded using a combination of growth factors
and small molecules (BMP4, Activin A, CHIR99021 and
SU5402) (Zhang et al., 2016b). The activation of Wnt sig-
naling by CHIR99021 not only promoted iCPC proliferation,
but also inhibited further differentiation of iCPCs into car-
diomyocytes. In addition, treating iCPC with Wnt inhibitor
IWP2 facilitated even more efﬁcient cardiac differentiation.
Reprogramming mouse and human ﬁbroblasts into
expandable cardiac progenitors by small molecules alone
could likely be achieved with further screening and modiﬁ-
cations in the future.
Cardiac ﬁbroblasts account for a majority of cells in the
heart and represent a potential cell source for cardiac
reprogramming. Direct in vivo cardiac reprogramming has
already demonstrated some promising results. Qian et al.
converted mouse resident non-myocytes into iCMs in vivo by
local delivery of GMT after coronary ligation (Qian et al.,
2012). Song et al. showed that GMT plus Hand2 could
cooperatively reprogram dividing non-cardiomyocytes into
functional iCMs in situ (Song et al., 2012). These cardiac
reprogramming TF-delivered hearts had decreased infarct
size and better cardiac function. Therefore, reprogramming
cardiac ﬁbroblasts to iCMs in their native environment by
chemical compounds will hold great potentials in cardiac
regenerative therapies.
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The liver is a fascinating organ that can regenerate itself; but
unfortunately, this remarkable capacity is lost in chronic liver
diseases. Currently, there are over 600 million people with
liver diseases and 1 million deaths per year worldwide.
Because the limitation of organ donors, cell-based therapy
may represent an attractive approach for treating life-
threatening liver failure, if a sufﬁcient amount of functional
hepatocytes can be generated from easily accessible cell
sources. Many research groups focus their efforts on the
generation of induced hepatocyte-like cells (iHeps) via
reprogramming approaches. In 2011, Huang et al. showed
that functional iHep cells could be converted from p19 null
mouse ﬁbroblasts via transduction of Gata4, Hnf1α, and
Foxa3 (Huang et al., 2011). Moreover, these iHep cells
restored liver functions in vivo and rescued the recipients
from death, which provided a promising proof of principle
example for the use in regenerative medicine. Meanwhile,
Sekiya et al. converted mouse embryonic and adult ﬁbrob-
lasts into iHep cells using a combination of Hnf4α plus
Foxa1, Foxa2 or Foxa3 (Sekiya and Suzuki, 2011).
Remarkably, after overexpressing Hnf1β and Foxa3, mouse
embryonic ﬁbroblasts were converted to induced hepatic
stem cells, which had the capability of long-term expansion
and bipotential differentiation to hepatocytes and cholan-
giocytes (Yu et al., 2013). Subsequently, human ﬁbroblasts
were successfully reprogrammed into iHep cells by different
combinations of TFs (Du et al., 2014; Huang et al., 2014).
Huang et al. generated human iHeps from ﬁbroblasts by
introduction of FOXA3, HNF1α, and HNF4α (Huang et al.,
2014). Meanwhile, Du et al. showed that human ﬁbroblasts
could be reprogrammed to functional iHeps by overex-
pressing HNF1α, HNF4α, HNF6, ATF5, PROX1, and CEBPα
(Du et al., 2014). These human iHeps expressed liver-
speciﬁc markers, and could integrate into mouse liver and
demonstrated many metabolic functions of the liver.
Recently, the non-viral and non-integrating transduction
systems, including synthetic RNAs, recombinant proteins,
and episomal plasmids, become more attractive (Fusaki
et al., 2009; Kim et al., 2009, 2015; Warren et al., 2010; Zhou
and Freed, 2009). For example, Simeonov et al. used a
method of repeating transfection with synthetic modiﬁed
mRNAs encoding hepatic reprogramming TFs and suc-
cessfully induced iHep cells from human ﬁbroblasts (Sime-
onov and Uppal, 2014). Kim et al. applied an oriP/EBNA1-
based episomal system to deliver a set of transcription fac-
tors, including Gata4, Hnf1α, and Foxa3, to convert ﬁbrob-
lasts into iHep cells (Kim et al., 2015). Small molecules also
played a critical role in iHep reprogramming process (Lim
et al., 2016; Pournasr et al., 2015). We previously generated
induced endodermal progenitor cells by the CASD lineage
conversion strategy, and greatly expanded these endoder-
mal progenitor cells by a chemically deﬁned condition, con-
sisting of EGF, bFGF, A83-01, and CHIR99021. Further
treatment with soluble growth factors and small molecules,
such as A83-01 and Compound E, these induced endoder-
mal progenitor cells efﬁciently differentiated into functional
hepatocytes. After transplantation, human iHeps integrated
into immunodeﬁcient mouse livers, expanded extensively,
and acquired mature hepatocyte functions (Zhu et al.,
2014b). Moreover, Lim et al. reported that direct conversion
into iHeps is a stepwise transition involving the sequential
erasure of somatic memory, MET transition, and induction of
hepatic cell fate (Lim et al., 2016). Through chemical
screening, they found that CHIR99021 and A83-01 facili-
tated one factor Hnf1α-induced hepatic reprogramming.
Mechanistically, these small molecules facilitated the robust
iHep generation through promoting MET process. In the
future, utilizing all-chemical method to induce iHep repro-
gramming will be a promising way to promote the develop-
ment of this ﬁeld.
More recently, in vivo hepatic reprogramming was fulﬁlled
by injection of hepatic reprogramming factors in situ (Rez-
vani et al., 2016; Song et al., 2016). Rezvani et al. developed
in vivo reprogramming of myoﬁbroblasts into hepatocytes
using adeno-associated virus (AAV) vectors expressing
hepatic transcription factors: Foxa1, Foxa2, Foxa3, Gata4,
Hnf1a, and Hnf4a. These iHeps converted from myoﬁbrob-
lsts were functional and reduced liver ﬁbrosis (Rezvani et al.,
2016). Song et al. showed that overexpression of FOXA3,
GATA4, HNF1A, and HNF4A could convert mouse myoﬁ-
broblasts into iHeps cells in ﬁbrotic mouse livers and also
reduced liver ﬁbrosis (Song et al., 2016). More efforts are
required to develop better delivery methods and improve the
conversion efﬁciency and cell maturity. Obviously, in vivo
hepatic reprogramming by small molecules will facilitate the
translation of the iHep technology into clinical treatment of
chronic liver diseases.
PANCREATIC REPROGRAMMING
Diabetes mellitus represents a global health epidemic and
affects more than 300 million people worldwide according to
the International Diabetes Federation. Diabetes is caused
and developed as a deﬁciency and/or dysfunction of pan-
creatic β cells. A key method to study diabetes and treat
patients is to obtain unlimited numbers of functional pan-
creatic β cells. Reprogramming other types of somatic cells
to pancreatic β cells is under active investigation. In 2005,
Minammi et al. reported that adult mouse pancreatic exo-
crine cells could be converted into insulin-producing cells
in vitro by suspension culture with EGF and nicotinamide
(Minami et al., 2005). In 2008, Zhou et al. reprogrammed
adult pancreatic exocrine cells to β-like cells in vivo by
introducing three TFs: Pdx1, Ngn3, and Mafa (Zhou et al.,
2008). Then, Li et al. developed an improved method for
in vivo pancreatic conversion (Li et al., 2014b). These
induced pancreatic β-like cells formed the islet-like struc-
tures and could persist in vivo for more than one year (Li
et al., 2014a). Additionally, Chen et al. reported that transient
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intestinal expression of Pdx1, Ngn3, and Mafa promoted
rapid conversion of intestinal crypt cells into endocrine cells
(Chen et al., 2014). Besides mouse cells, human pancreatic
ductal cells could also be converted into pancreatic β-like
cells by overexpression of PDX1, NGN3, MAFA, and PAX6
(Lee et al., 2013). These converted pancreatic β-like cells
could secrete insulin in response to high concentration of
glucose. More interestingly, Ariyachet et al. reported that
cells of the antral stomach were ideal cell source for pan-
creatic reprogramming (Ariyachet et al., 2016). These
reprogrammed insulin+ β-like cells performed molecularly
and functionally similar to bona ﬁde pancreatic β cells. These
results suggested that the initial cell type can affect the
reprogramming efﬁciency and induced cell phenotype and its
functional properties.
Introducing exogenous genetic material and altering the
genome raise safety concerns (Barrilleaux and Knoepﬂer,
2011). Therefore, using small molecules to active endoge-
nous TFs is an attractive method for cellular reprogramming.
By high-throughput screening, BRD7552 was shown to be an
inducer of PDX1 expression (Yuan et al., 2013). In another
report, DNA methyltransferase inhibitor 5-aza-dC was cap-
able of increasing the expression of Ngn3 in PANC-1 cells
(Lefebvre et al., 2010). In our previous study, we found that
several speciﬁc small molecules could enhance the endo-
dermal conversion process, including CHIR99021, NaB,
Parnate, RG108, and 5’-N-ethylcarboxamidoadenosine, and
promote pancreatic β-like cell differentiation and maturation,
including Compound E, Vitamin C, and Bayk8644 (Zhu et al.,
2016). More recently, Wang et al. described the derivation of
human induced endodermal progenitor cells from gastroin-
testinal epithelial cells using a cocktail of deﬁned small
molecules, including Bayk8644, BIX01294, RG108, and
SB431542, along with support from tissue-speciﬁc mes-
enchymal feeders (Wang et al., 2016). Induced endodermal
progenitor cells could subsequently differentiate into more
speciﬁed cell types, including pancreatic β-like cells. How-
ever, the therapeutic potentials of these pancreatic β-like cells
have not been investigated so far. Obviously, using small
molecules to replace master TFs as well as promote repro-
gramming to mature pancreatic β cells is a promising therapy
for treating diabetes. However, transferring these ﬁndings for
efﬁcient in vivo pancreatic reprogramming, preferably be an
all-chemical approach is waiting to be achieved in the future.
PERSPECTIVE
Cell fate transition and regeneration have fascinated biolo-
gists for centuries. After the discovery of iPSC technology, a
lot of progress has been made in TF-mediated cellular
reprogramming into many different deﬁned cell types.
Compared with the introduction of TFs by viral methods,
small molecules have several advantages, can enhance
reprogramming efﬁciency and improve the quality of the
reprogrammed cells. Currently, identiﬁcation of novel and
effective small molecules for cellular reprogramming remains
very labor intense. New technologies, such as high-
throughput screening (HTS2) platform (Li et al., 2012) and
reporter systems generated by CRISPR tools (Hockemeyer
and Jaenisch, 2016), can be applied to this ﬁeld and will
accelerate the discovery process. In addition, the molecular
mechanisms of most reprogramming processes are largely
unknown, and how TFs or small molecules mediate cell fate
transitions is still unclear. New technologies, such as single-
cell analysis (Wen and Tang, 2016) and CRISPR-based
genome-wide screening (Shalem et al., 2014), can provide
new insights and help us to better understand the underlying
molecular mechanisms. A better understanding of the
detailed mechanisms during reprogramming processes can
also help to improve the reprogramming efﬁciency and
acquire mature cells with complete functionality for disease
modeling, drug development, and cell-based transplantation
(Fig. 2). Optimistically, future studies in cellular reprogram-
ming by small molecules will overcome current hurdles,
generate new discoveries, and beneﬁt human health.
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